Loading data for TLX — first visit, this takes a few seconds.
Telix Pharmaceuticals Lim... (TLX)
NasdaqGS: TLX
· Real-Time Price · USD
11.33
-1.09 (-8.78%)
At close: Aug 24, 2026, 4:41 PM
The price, the headline numbers and the latest news, in one place.
Telix Pharmaceuticals Limited (TLX) Stock Price, Analysis & Data
-8.78% (1D)
No data available
| Bid | 11.32 |
| Market Cap | 3.96B |
| Revenue (ttm) | 890.79M |
| Net Income (ttm) | 33.5M |
| 0.60 | |
| 0.1 | |
| 116.8 | |
| 80.3 | |
| P/B (ttm) | 9.53 |
| P/S (ttm) | 4.44 |
| Earnings Date | n/a |
| Ask | 10.32 |
| Volume | 299,199 |
| Avg. Volume (20D) | 162,888 |
| Open | 11.34 |
| Previous Close | 12.42 |
| Day's Range | 11.19 - 11.39 |
| 52-Week Range | 6.28 - 12.58 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with adv...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2024
Employees 1,120
Stock Exchange NasdaqGS
Ticker Symbol TLX
Website https://telixpharma.com
Financial Performance
In 2025, Telix Pharmaceuticals's revenue was 803.79M, an increase of 55.61% compared to the previous year's 516.55M. Earnings were -7.13M, a decrease of -121.15%.
Financial Statements
Page 1 of 2